208 related articles for article (PubMed ID: 34905282)
21. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
Stevens TW; Haasnoot ML; D'Haens GR; Buskens CJ; de Groof EJ; Eshuis EJ; Gardenbroek TJ; Mol B; Stokkers PCF; Bemelman WA; Ponsioen CY;
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):900-907. PubMed ID: 32619413
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity-score matched cohort analysis.
Narula N; Wong ECL; AlRamdan R; Bualbanat H; Marshall JK; Steinhart AH; Greener T; Silverberg MS
J Gastroenterol Hepatol; 2021 Oct; 36(10):2803-2812. PubMed ID: 34020510
[TBL] [Abstract][Full Text] [Related]
23. Effects of Preoperative Anti-TNF Therapy on Specimen Length in Crohn's Disease and Beyond.
Allaix ME; Resegotti A; Morino M
J Invest Surg; 2022 Jun; 35(6):1366-1367. PubMed ID: 35249425
[No Abstract] [Full Text] [Related]
24. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
[TBL] [Abstract][Full Text] [Related]
25. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
[TBL] [Abstract][Full Text] [Related]
26. Infliximab, Immunomodulators and Treatment Failures in Paediatric and Adolescent Patients with Crohn's Disease: a Nationwide Cohort Study.
Lund K; Larsen MD; Knudsen T; Kjeldsen J; Nielsen RG; Mertz Nørgård B
J Crohns Colitis; 2021 Apr; 15(4):575-582. PubMed ID: 32926166
[TBL] [Abstract][Full Text] [Related]
27. Early Anti-Tumor-Necrosis-Factor Therapy for Crohn's Disease-Related Abdominal Abscesses and Phlegmon in Children.
Constant BD; de Zoeten EF; Weinman JP; Albenberg L; Scott FI
Dig Dis Sci; 2023 Mar; 68(3):877-888. PubMed ID: 35790702
[TBL] [Abstract][Full Text] [Related]
28. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
Doecke JD; Hartnell F; Bampton P; Bell S; Mahy G; Grover Z; Lewindon P; Jones LV; Sewell K; Krishnaprasad K; Prosser R; Marr D; Fischer J; R Thomas G; Tehan JV; Ding NS; Cooke SE; Moss K; Sechi A; De Cruz P; Grafton R; Connor SJ; Lawrance IC; Gearry RB; Andrews JM; Radford-Smith GL;
Aliment Pharmacol Ther; 2017 Feb; 45(4):542-552. PubMed ID: 27995633
[TBL] [Abstract][Full Text] [Related]
29. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
[TBL] [Abstract][Full Text] [Related]
30. Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study.
D'Amico F; Peyrin-Biroulet L; Vandromme L; Bouhnik Y; Faure P; Nahon S; Hagege H; Hebuterne X; Benkhalifa S; Nachury M
Dig Liver Dis; 2020 Sep; 52(9):995-1001. PubMed ID: 32532602
[TBL] [Abstract][Full Text] [Related]
31. Antitumour necrosis factor alpha treatment in Crohn's disease: long-term efficacy, side effects and need for surgery.
Lerang F; Holst R; Henriksen M; Wåhlberg H; Jelsness-Jørgensen LP
Scand J Gastroenterol; 2022 Aug; 57(8):921-929. PubMed ID: 35188443
[TBL] [Abstract][Full Text] [Related]
32. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
34. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease.
Song JH; Hong SN; Lee JE; Kim K; Kim TJ; Kim ER; Chang DK; Kim YH
Scand J Gastroenterol; 2019 Jul; 54(7):876-885. PubMed ID: 31303093
[No Abstract] [Full Text] [Related]
35. Prevention of post-operative recurrence of Crohn's disease among patients with prior anti-TNFα failure: A retrospective multicenter study.
Le Cosquer G; Altwegg R; Rivière P; Bournet B; Boivineau L; Poullenot F; Bozon A; Buscail L; Laharie D; Gilletta C
Dig Liver Dis; 2023 Jun; 55(6):727-734. PubMed ID: 36192340
[TBL] [Abstract][Full Text] [Related]
36. Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study.
Olén O; Erichsen R; Sachs MC; Pedersen L; Halfvarson J; Askling J; Ekbom A; Sørensen HT; Ludvigsson JF
Lancet Gastroenterol Hepatol; 2020 May; 5(5):475-484. PubMed ID: 32066530
[TBL] [Abstract][Full Text] [Related]
37. Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage.
Panchal H; Wagner M; Chatterji M; Taouli B; McBride R; Patterson JR; Ungaro R; Dubinsky M; Cho J; Sachar DB
Dig Dis Sci; 2019 Nov; 64(11):3274-3283. PubMed ID: 30607690
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
Bouhnik Y; Carbonnel F; Laharie D; Stefanescu C; Hébuterne X; Abitbol V; Nachury M; Brixi H; Bourreille A; Picon L; Bourrier A; Allez M; Peyrin-Biroulet L; Moreau J; Savoye G; Fumery M; Nancey S; Roblin X; Altwegg R; Bouguen G; Bommelaer G; Danese S; Louis E; Zappa M; Mary JY;
Gut; 2018 Jan; 67(1):53-60. PubMed ID: 28119352
[TBL] [Abstract][Full Text] [Related]
39. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease.
Hradsky O; Kazeka D; Copova I; Lerchova T; Mitrova K; Pospisilova K; Sulovcova M; Zarubova K; Bronsky J
Eur J Pediatr; 2021 Sep; 180(9):3001-3008. PubMed ID: 33876264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
